Qiuping Ye
Qiuping Ye has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Athena Sudom
Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
1 shared publicationCraig Tomooka
Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
1 shared publication- Daqing Sun
Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
1 shared publication - Daqing Sun
Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
1 shared publication Dustin L. McMinn
Departments of Therapeutic Discovery, Metabolic Disorders, and Pharmacokinetics and Drug Metabolism, Amgen, Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States
1 shared publicationHua Tu
Departments of Therapeutic Discovery, Metabolic Disorders, and Pharmacokinetics and Drug Metabolism, Amgen, Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States
1 shared publication
Latest Publications
- 1 December 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (23) , 5546-5550
Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4
- 1 December 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (23) , 5546-5550
Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4
- 30 September 2014
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 5 (11) , 1245-1250
Synthesis, in Vitro Covalent Binding Evaluation, and Metabolism of 14C-Labeled Inhibitors of 11β-HSD1
In this letter, we reported the design and synthesis of three potent, selective, and orally bioavailable 11β-HSD1 inhibitors labeled with 14C: AMG 456 (1), AM-6949 (2), and AM-7715 (3). We evaluated the covalent protein binding of the labeled inhibitors in human liver microsomes in vitro and assessed their potential bioactivation risk in humans. We then studied the in vitro mechanism of 2 in human hepatocytes and the formation of reactive intermediates. Our study results suggest that 1 and 3 have low potential for metabolic bioactivation in humans, while 2 has relatively high risk.
- 30 September 2014
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 5 (11) , 1245-1250
Synthesis, in Vitro Covalent Binding Evaluation, and Metabolism of 14C-Labeled Inhibitors of 11β-HSD1
In this letter, we reported the design and synthesis of three potent, selective, and orally bioavailable 11β-HSD1 inhibitors labeled with 14C: AMG 456 (1), AM-6949 (2), and AM-7715 (3). We evaluated the covalent protein binding of the labeled inhibitors in human liver microsomes in vitro and assessed their potential bioactivation risk in humans. We then studied the in vitro mechanism of 2 in human hepatocytes and the formation of reactive intermediates. Our study results suggest that 1 and 3 have low potential for metabolic bioactivation in humans, while 2 has relatively high risk.